Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily.

Abstract

The authors evaluated the efficacy of once-daily treatment with levobunolol in patients with primary open-angle glaucoma or ocular hypertension in an open-labeled, two-phase titration clinical trial. All patients started the study using 0.25% levobunolol administered once daily for 3 months (phase I). If a patient's intraocular pressure (IOP) was not controlled with this concentration of levobunolol, the concentration was increased to 0.5% administered once daily for 3 months (phase II). During phase I, a significant reduction in IOP was observed in 21 of the 29 patients (72%), with an average IOP reduction of 24%. During phase II, in six patients whose IOP was reduced inadequately with 0.25% levobunolol, one had a significant reduction in IOP with 0.5% levobunolol. The authors concluded that levobunolol, instilled once daily at a concentration of 0.25%, was effective in significantly reducing IOP in the majority of the patients evaluated.

• Authors: T Wandel, D Fishman, G D Novack, E Kelley, K K Chen
• Journal: Ophthalmology (Ophthalmology) Vol. 95 Issue 2 Pg. 252-5 (Feb 1988) ISSN: 0161-6420 [Print] United States
• PMID: 3050679 (Publication Type: Journal Article)

Chemical References

• Ophthalmic Solutions
• Levobunolol

Topics

• Adult
• Aged
• Aged, 80 and over
• Drug Administration Schedule
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Levobunolol (administration & dosage)
• Male
• Middle Aged
• Ocular Hypertension (drug therapy)
• Ophthalmic Solutions